ArticleAntimicrobial agents and chemotherapy2019
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.Health technology assessment (Winchester, England) · 2024Pooled it
- Prevalence of colistin resistance in clinical isolates ofFrontiers in microbiology · 2024Pooled it
- Mind the governance gap: a one health scoping review of national AMR performance indicators.npj antimicrobials and resistance · 2026Article
- An Antimicrobial susceptibility study to compare the in vitro activity of antimicrobial agents in the Philippines against Enterobacterales and Pseudomonas aeruginosa from different infection sites: results from ATLAS surveillance program (2018-2021).BMC infectious diseases · 2026Article
- Expanding Threat of Carbapenemase-ProducingbioRxiv : the preprint server for biology · 2026Article
- Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates obtained from patients treated in a paediatric hospital in Mexico.Scientific reports · 2026Article
- Genomic characterization of an ESBL-producingMicrobiology spectrum · 2025Article
- Efficacy of Imipenem/Cilastatin/Relebactam in infections caused by Difficult-to-Treat Gram-Negative Bacteria: A Retrospective Analysis of Real-world data in Greece.Le infezioni in medicina · 2025Article
- Activity of ceftolozane/tazobactam and imipenem/relebactam against Gram-negative clinical isolates collected in Mexico-SMART 2017-2021.JAC-antimicrobial resistance · 2024Article
- Article
- Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam.WIREs mechanisms of disease · 2022Review
- The Dynamics of Antimicrobial Resistance among Enterobacteriaceae Isolates in Russia: Results of the 2012-2018 INFORM and ATLAS International Program Studies.Antibiotics (Basel, Switzerland) · 2022Article
- Antibiotics in the pipeline: a literature review (2017-2020).Infection · 2022Review
- Geographic Patterns of Carbapenem-Resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015-2019.Antimicrobial agents and chemotherapy · 2022Article
- Acquisition of resistance to ceftazidime-avibactam during infection treatment inFrontiers in cellular and infection microbiology · 2022Article
- In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).BMC infectious diseases · 2021Article
- New β-Lactam-β-Lactamase Inhibitor Combinations.Clinical microbiology reviews · 2020Review
- Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".Infectious disease clinics of North America · 2020Review
- Review
- In vitro activity of ceftazidime/avibactam and comparators against Gram-negative bacterial isolates collected from Latin American centres between 2015 and 2017.The Journal of antimicrobial chemotherapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The International Network for Optimal Resistance Monitoring (INFORM) global surveillance program collected clinical isolates of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.